Clover Health Investments Corp. - Class A (CLOV) closed at $4.80 on October 20, 2026, up 8.1% from the previous close, on volume of 3,337,325 shares (30-day average 4,311,024).
Data as of October 20, 2026.
Globe Newswire (Mon, 19-Oct 4:30 PM ET)
Market Chameleon (Fri, 9-Oct 7:48 AM ET)
Clover Health’s wide-network PPO earns a 5-Star CMS rating for 2027, unlocking year-round enrollment
Market Chameleon (Fri, 9-Oct 3:06 AM ET)
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
Globe Newswire (Thu, 8-Oct 6:45 PM ET)
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 7-Oct 4:05 PM ET)
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Globe Newswire (Thu, 1-Oct 8:00 AM ET)
Globe Newswire (Thu, 24-Sep 5:55 PM ET)
Globe Newswire (Thu, 24-Sep 4:30 PM ET)
Clover Health to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 31-Aug 4:05 PM ET)
Clover Health Reports Second Quarter 2026 Results
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of October 21, 2026, CLOV stock price declined to $4.78 with 1,291,001 million shares trading.
CLOV has a beta of 2.77, meaning it tends to be more sensitive to market movements. CLOV has a correlation of 0.21 to the broad based SPY ETF.
CLOV has a market cap of $2.54 billion. This is considered a Mid Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $743 million in Revenue and $.05 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.01.
In the last 3 years, CLOV traded as high as $5.59 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
CLOV has outperformed the market in the last year with a price return of +63.7% while the SPY ETF gained +16.3%. CLOV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.2% and +3.9%, respectively, while the SPY returned +4.4% and -0.8%, respectively.
CLOV support price is $4.61 and resistance is $4.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV shares will trade within this expected range on the day.
